Growth Metrics

Amicus Therapeutics (FOLD) Shares Outstanding (Weighted Average) (2016 - 2025)

Amicus Therapeutics' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $308.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 1.31% year-over-year to $308.4 million, compared with a TTM value of $308.4 million through Dec 2025, up 1.31%, and an annual FY2025 reading of $308.4 million, up 1.31% over the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $308.4 million at Amicus Therapeutics, roughly flat from $308.5 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $308.5 million in Q3 2025, with the low at $265.4 million in Q2 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $295.9 million, with a median of $299.0 million recorded in 2023.
  • Year-over-year, Shares Outstanding (Weighted Average) rose 6.5% in 2022 and then grew 0.99% in 2023.
  • Tracing FOLD's Shares Outstanding (Weighted Average) over 5 years: stood at $271.4 million in 2021, then rose by 6.5% to $289.1 million in 2022, then increased by 2.11% to $295.2 million in 2023, then increased by 3.12% to $304.4 million in 2024, then increased by 1.31% to $308.4 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Shares Outstanding (Weighted Average) are $308.4 million (Q4 2025), $308.5 million (Q3 2025), and $308.3 million (Q2 2025).